Generic Prevymis Availability

Last updated on Jul 9, 2025.

Prevymis is a brand name of letermovir, approved by the FDA in the following formulation(s):

PREVYMIS (letermovir - pellets;oral)

• Manufacturer: MSD
  Approval date: August 30, 2024
  Strength(s): 20MG/PACKET ^[RLD], 120MG/PACKET ^[RLD]

PREVYMIS (letermovir - solution;intravenous)

• Manufacturer: MERCK SHARP DOHME
  Approval date: November 8, 2017
  Strength(s): 240MG/12ML (20MG/ML) ^[RLD], 480MG/24ML (20MG/ML) ^[RLD]

PREVYMIS (letermovir - tablet;oral)

• Manufacturer: MERCK SHARP DOHME
  Approval date: November 8, 2017
  Strength(s): 240MG ^[RLD], 480MG ^[RLD]

Is there a generic version of Prevymis available?

No. There is currently no therapeutically equivalent version of Prevymis available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prevymis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
  Patent 10,603,384
  Issued: March 31, 2020
  Inventor(s): Paulus Kerstin & Schwab Wilfried & Grunder Dominique & Van Hoogevest Peter
  Assignee(s): AICURIS GMBH & CO. KG
  

  The invention relates to pharmaceutical compositions, particularly for intravenous administration, containing {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid in combination with at least one of the cyclodextrin excipients, lysine and arginine; the method for its production; and its use in methods of treatment of and/or as a prophylactic for illnesses, particularly its use as an antiviral, preferably against cytomegaloviruses.

  Patent expiration dates:

  • February 28, 2033
    
    ✓ 
    Drug product
• Substituted dihydroquinazolines
  Patent RE46791
  Issued: April 17, 2018
  Inventor(s): Wunberg Tobias & Baumeister Judith & Betz Ulrich & Jeske Mario & Lampe Thomas & Nikolic Susanne & Reefschlager Jurgen & Schohe-Loop Rudolf & Sussmeier Frank & Zimmermann Holger & Grosser Rolf & Henninger Kerstin & Hewlett Guy & Keldenich Jorg & Lang Dieter & Nell Peter
  Assignee(s): AICURIS ANTI-INFECTIVE CURES GMBH
  

  The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.

  Patent expiration dates:

  • January 18, 2029
    
    ✓ 
    Drug substance
    ✓ 
    Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • June 5, 2026 - PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT RECIPIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE [D+/R-])
  • August 2, 2026 - EXTENSION OF LETERMOVIR DOSING REGIMEN FROM 100 TO 200 DAYS POST-TRANSPLANT FOR THE PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE IN ADULT CMV SEROPOSITIVE RECIPIENTS (R+) OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT WHO ARE AT RISK FO
  • August 30, 2027 - NEW PATIENT POPULATION
  • August 30, 2027 - NEW PRODUCT
  • June 5, 2030 - FOR PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT RECIPIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE [D+/R-])
  • June 5, 2030 - FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S). AN APPLICATION S
  • August 30, 2031 - PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) DISEASE IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 40 KG WHO ARE KIDNEY TRANSPLANT RECIPIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE [D+/R-])
  • August 30, 2031 - PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE IN PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER AND WEIGHING AT LEAST 6 KG WHO ARE CMV-SEROPOSITIVE RECIPIENTS [R+] OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer